Oculis lists at Nasdaq through SPAC merger

Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash balance exceeding $117m, prior to payment of final transaction costs. Oculis is supported by leading new and existing institutional investors in the upsized PIPE financing including LSP 7, funds managed by Tekla Capital Management LLC, Earlybird, Novartis Venture Fund, Pivotal Life Sciences and VI Partners, among others.

Oculis’ pipeline includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Riad Sherif MD, CEO of Oculis, commented: „Listing on the Nasdaq Stock Market is a confirmation of the potential of Oculis’ pipeline to bring significant value for patients, physicians and investors. Oculis‘ robust financial position enables the advancement of multiple clinical stage candidates and the delivery of several important near-term catalysts for value creation, including potentially OCS-01, OCS-02, and OCS-05.

Anthony Rosenberg will continue to serve as Chairman of the Board of Directors of Oculis AG, which now includes Christina Ackermann, Lionel Carnot, Pravin Dugel M.D., Martijn Kleijwegt, Geraldine O’Keeffe and Riad Sherif M.D.